Serotonin and GI disorders: An update on clinical and experimental studies

Clinical and Translational Gastroenterology

Volumn 3, Issue , 2012, Pages

  Manocha, Marcus ^a   Khan, Waliul I ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN;

CELIAC DISEASE; CELL DIFFERENTIATION; CLINICAL STUDY; COLITIS; CYTOLOGY; ENTERITIS; ENTEROCHROMAFFIN CELL; EXPERIMENTAL STUDY; GASTROINTESTINAL DISEASE; HUMAN; IMMUNE RESPONSE; INTESTINE DIVERTICULOSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEROTONIN METABOLISM; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM;

EID: 84861862174     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2012.8     Document Type: Review

References (86)

1. Rapport MM, Green AA, Page IH. Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem 1948; 176: 1243-1251.
2. Erspamer V. Historical introduction: the Italian contribution to the discovery of 5-hydroxytryptamine (enteramine, serotonin). J Hypertens Suppl 1986; 4: S3-S5.
3. Coates MD, Mahoney CR, Linden DR et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 1657-1664. (Pubitemid 38736329)
4. Magro F, Vieira-Coelho MA, Fraga S et al. Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci 2002; 47: 216-224. (Pubitemid 34075041)
5. Miwa J, Echizen H, Matsueda K et al. Patients with constipation- predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits. Digestion 2001; 63: 188-194.
6. Faure C, Patey N, Gauthier C et al. Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology 2010; 139: 249-258.
7. Coleman NS, Foley S, Dunlop SP et al. Abnormalities of serotonin metabolism and their relation to symptoms in untreated celiac disease. Clin Gastroenterol Hepatol 2006; 4: 874-881. (Pubitemid 43994540)
8. Ataee R, Ajdary S, Zarrindast M et al. Anti-mitogenic and apoptotic effects of 5-HT1B receptor antagonist on HT29 colorectal cancer cell line. J Cancer Res Clin Oncol 2010; 136: 1461-1469.
9. Coogan PF, Strom BL, Rosenberg L. Antidepressant use and colorectal cancer risk. Pharmacoepidemiol Drug Saf 2009; 18: 1111-1114.
10. Costedio MM, Coates MD, Danielson AB et al. Serotonin signaling in diverticular disease. J Gastrointest Surg 2008; 12: 1439-1445.
11. Moran GW, Leslie FC, Levison SE et al. Enteroendocrine cells: neglected players in gastrointestinal disorders? Therap Adv Gastroenterol 2008; 1: 51-60.
12. Sjolund K, Sanden G, Hakanson R et al. Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology 1983; 85: 1120-1130. (Pubitemid 13007805)
13. Spiller R. Serotonin and GI clinical disorders. Neuropharmacology 2008; 55: 1072-1080.
14. de Bruine AP, Dinjens WN, Zijlema JH et al. Renewal of enterochromaffin cells in the rat caecum. Anat Rec 1992; 233: 75-82.
15. May R, Sureban SM, Hoang N et al. Doublecortin and CaM kinase-like-1 and leucine-richrepeat- containing G-protein-coupled receptor mark quiescent and cycling intestinal stem cells, respectively. Stem Cells 2009; 27: 2571-2579.
16. Kosinski C, Li VS, Chan AS et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci USA 2007; 104: 15418-15423. (Pubitemid 47502932)
17. Rubin DC. Intestinal morphogenesis. Curr Opin Gastroenterol 2007; 23: 111-114. (Pubitemid 46192963)
18. Crosnier C, Stamataki D, Lewis J. Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat Rev Genet 2006; 7: 349-359.
19. Jensen J, Pedersen EE, Galante P et al. Control of endodermal endocrine development by Hes-1. Nat Genet 2000; 24: 36-44. (Pubitemid 30041417)
20. Grapin-Botton A, Majithia AR, Melton DA. Key events of pancreas formation are triggered in gut endoderm by ectopic expression of pancreatic regulatory genes. Genes Dev 2001; 15: 444-454. (Pubitemid 32187005)
21. Yang Q, Bermingham NA, Finegold MJ et al. Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science 2001; 294: 2155-2158. (Pubitemid 33150670)
22. Lee CS, Perreault N, Brestelli JE et al. Neurogenin 3 is essential for the proper specification of gastric enteroendocrine cells and the maintenance of gastric epithelial cell identity. Genes Dev 2002; 16: 1488-1497. (Pubitemid 34686330)
23. Bjerknes M, Cheng H. Neurogenin 3 and the enteroendocrine cell lineage in the adult mouse small intestinal epithelium. Dev Biol 2006; 300: 722-735. (Pubitemid 44914135)
24. Walther DJ, Peter JU, Bashammakh S et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003; 299: 76. (Pubitemid 36042402)
25. Walther DJ, Bader M. A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 2003; 66: 1673-1680. (Pubitemid 37249312)
26. Hakanson R, Owman C, Sjoberg NO et al. Amine mechanisms in enterochromaffin and enterochromaffin-like cells of gastric mucosa in various mammals. Histochemie 1970; 21: 189-220.
27. Schafermeyer A, Gratzl M, Rad R et al. Isolation and receptor profiling of ileal enterochromaffin cells. Acta Physiol Scand 2004; 182: 53-62. (Pubitemid 39223066)
28. Fujimiya M, Okumiya K, Kuwahara A. Immunoelectron microscopic study of the luminal release of serotonin from rat enterochromaffin cells induced by high intraluminal pressure. Histochem Cell Biol 1997; 108: 105-113. (Pubitemid 27362336)
29. Fukumoto S, Tatewaki M, Yamada T et al. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1269-R1276. (Pubitemid 36457570)
30. Bearcroft CP, Perrett D, Farthing MJ. 5-hydroxytryptamine release into human jejunum by cholera toxin. Gut 1996; 39: 528-531. (Pubitemid 26376034)
31. Kim M, Cooke HJ, Javed NH et al. D-glucose releases 5-hydroxytryptamine from human BON cells as a model of enterochromaffin cells. Gastroenterology 2001; 121: 1400-1406. (Pubitemid 33140457)
32. Wade PR, Westfall JA. Ultrastructure of enterochromaffin cells and associated neural and vascular elements in the mouse duodenum. Cell Tissue Res 1985; 241: 557-563. (Pubitemid 15024601)
33. Yang GB, Lackner AA. Proximity between 5-HT secreting enteroendocrine cells and lymphocytes in the gut mucosa of rhesus macaques (Macaca mulatta) is suggestive of a role for enterochromaffin cell 5-HT in mucosal immunity. J Neuroimmunol 2004; 146: 46-49. (Pubitemid 38032955)
34. Wang H, Steeds J, Motomura Y et al. CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection. Gut 2007; 56: 949-957. (Pubitemid 46999078)
35. Ghia JE, Li N, Wang H et al. Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology 2009; 137: 1649-1660.
36. Motomura Y, Ghia JE, Wang H et al. Enterochromaffin cell and 5-hydroxytryptamine responses to the same infectious agent differ in Th1 and Th2 dominant environments. Gut 2008; 57: 475-481. (Pubitemid 351442531)
37. Spiller R. Serotonin, inflammation, and IBS: fitting the jigsaw together? J Pediatr Gastroenterol Nutr 2007; 45 (Suppl 2): S115-S119.
38. Cloez-Tayarani I, Changeux JP. Nicotine and serotonin in immune regulation and inflammatory processes: a perspective. J Leukoc Biol 2007; 81: 599-606. (Pubitemid 46393537)
39. Kushnir-Sukhov NM, Brown JM, Wu Y et al. Human mast cells are capable of serotonin synthesis and release. J Allergy Clin Immunol 2007; 119: 498-499. (Pubitemid 46204791)
40. Nakamura K, Sato T, Ohashi A et al. Role of a serotonin precursor in development of gut microvilli. Am J Pathol 2008; 172: 333-344. (Pubitemid 351282021)
41. O'Connell PJ, Wang X, Leon-Ponte M et al. A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells. Blood 2006; 107: 1010-1017.
42. Muller T, Durk T, Blumenthal B et al. 5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo. PLoS One 2009; 4: e6453.
43. Boehme SA, Lio FM, Sikora L et al. Cutting edge: serotonin is a chemotactic factor for eosinophils and functions additively with eotaxin. J Immunol 2004; 173: 3599-3603. (Pubitemid 39280718)
44. Kushnir-Sukhov NM, Gilfillan AM, Coleman JW et al. 5-hydroxytryptamine induces mast cell adhesion and migration. J Immunol 2006; 177: 6422-6432. (Pubitemid 44628861)
45. Idzko M, Panther E, Stratz C et al. The serotoninergic receptors of human dendritic cells: identification and coupling to cytokine release. J Immunol 2004; 172: 6011-6019. (Pubitemid 38621202)
46. Li N, Ghia JE, Wang H et al. Serotonin activates dendritic cell function in the context of gut inflammation. Am J Pathol 2011; 178: 662-671.
47. Oshima S, Fujimura M, Fukimiya M. Changes in number of serotonin-containing cells and serotonin levels in the intestinal mucosa of rats with colitis induced by dextran sodium sulfate. Histochem Cell Biol 1999; 112: 257-263. (Pubitemid 29515492)
48. Linden DR, Chen JX, Gershon MD et al. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol 2003; 285: G207-G216. (Pubitemid 36736404)
49. Bischoff SC, Mailer R, Pabst O et al. Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice. Am J Physiol Gastrointest Liver Physiol 2009; 296: G685-G695.
50. Haub S, Ritze Y, Bergheim I et al. Enhancement of intestinal inflammation in mice lacking interleukin 10 by deletion of the serotonin reuptake transporter. Neurogastroenterol Motil 2010; 22: 826-834, e229.
51. Foley S, Garsed K, Singh G et al. Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology 2011; 140: 1434-1443, e1.
52. Camilleri M. Serotonin in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes 2009; 16: 53-59.
53. Gershon MD. Serotonin: its role and receptors in enteric neurotransmission. Adv Exp Med Biol 1991; 294: 221-230.
54. Ladabaum U. Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications. Aliment Pharmacol Ther 2003; 17: 1021-1030. (Pubitemid 36560802)
55. Stefulj J, Cicin-Sain L, Schauenstein K et al. Serotonin and immune response: effect of the amine on in vitro proliferation of rat lymphocytes. Neuroimmunomodulation 2001; 9: 103-108. (Pubitemid 32830599)
56. Laberge S, Cruikshank WW, Beer DJ et al. Secretion of IL-16 (lymphocyte chemoattractant factor) from serotonin-stimulated CD8+ T cells in vitro. J Immunol 1996; 156: 310-315.
57. Brown PM, Drossman DA, Wood AJ et al. The tryptophan hydroxylase inhibitor LX1031 is effective for patients with nonconstipating irritable bowel syndrome. Gastroenterology 2011; 141: 507-516.
58. Sanger GJ. 5-Hydroxytryptamine and the gastrointestinal tract: where next? Trends Pharmacol Sci 2008; 29: 465-471.
59. Rubinstein A. Approaches and opportunities in colon-specific drug delivery. Crit Rev Ther Drug Carrier Syst 1995; 12: 101-149.
60. El-Salhy M, Danielsson A, Stenling R et al. Colonic endocrine cells in inflammatory bowel disease. J Intern Med 1997; 242: 413-419. (Pubitemid 27513108)
61. Wheatcroft J, Wakelin D, Smith A et al. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil 2005; 17: 863-870. (Pubitemid 41748282)
62. Ahonen A, Kyosola K, Penttila O. Enterochromaffin cells in macrophages in ulcerative colitis and irritable colon. Ann Clin Res 1976; 8: 1-7.
63. Belai A, Boulos PB, Robson T et al. Neurochemical coding in the small intestine of patients with Crohn0s disease. Gut 1997; 40: 767-774. (Pubitemid 27305470)
64. Bishop AE, Pietroletti R, Taat CW et al. Increased populations of endocrine cells in Crohn0s ileitis. Virchows Arch A Pathol Anat Histopathol 1987; 410: 391-396. (Pubitemid 17022443)
65. Simren M, Axelsson J, Gillberg R et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002; 97: 389-396. (Pubitemid 34160766)
66. Fernandez-Banares F, Esteve M, Espinos JC et al. Drug consumption and the risk of microscopic colitis. Am J Gastroenterol 2007; 102: 324-330. (Pubitemid 46160546)
67. Mawe GM, Coates MD, Moses PL. Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 1067-1076. (Pubitemid 43779345)
68. Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol 2004; 141: 1285-1293. (Pubitemid 38638817)
69. Cremon C, Carini G, Wang B et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 2011; 106: 1290-1298.
70. Malinen E, Krogius-Kurikka L, Lyra A et al. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J Gastroenterol 2010; 16: 4532-4540.
71. Moyana TN, Shukoor S. Gastrointestinal endocrine cell hyperplasia in celiac disease: a selective proliferative process of serotonergic cells. Mod Pathol 1991; 4: 419-423.
72. Wheeler EE, Challacombe DN. Quantification of enterochromaffin cells with serotonin immunoreactivity in the duodenal mucosa in coeliac disease. Arch Dis Child 1984; 59: 523-527. (Pubitemid 14122081)
73. Challacombe DN, Dawkins PD, Baker P. Increased tissue concentrations of 5-hydroxytryptamine in the duodenal mucosa of patients with coeliac disease. Gut 1977; 18: 882-886. (Pubitemid 8230165)
74. Foley KF, Pantano C, Ciolino A et al. IFN-gamma and TNF-alpha decrease serotonin transporter function and expression in Caco2 cells. Am J Physiol Gastrointest Liver Physiol 2007; 292: G779-G784. (Pubitemid 46440381)
75. Margolis KG, Stevanovic KD, Yang QM et al. An inhibitor of tryptophan hydroxylase successfully ameliorates TNBS-induced colitis. Gastroenterology 2011; 140: S478-S478.
76. Kim JJ, Wang HQ, Ghia JE et al. Inhibition of 5-HT signaling by blocking 5-HT7 receptor function alleviates colitis. Gastroenterology 2011; 140: S26-S26.
77. Kidd M, Gustafsson BI, Drozdov I et al. IL1beta- and LPS-induced serotonin secretion is increased in EC cells derived from Crohn's disease. Neurogastroenterol Motil 2009; 21: 439-450.
78. Minderhoud IM, Oldenburg B, Schipper ME et al. Serotonin synthesis and uptake in symptomatic patients with Crohn0s disease in remission. Clin Gastroenterol Hepatol 2007; 5: 714-720. (Pubitemid 46830050)
79. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397-414. (Pubitemid 46127672)
80. Beattie DT, Smith JA. Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol 2008; 377: 181-203.
81. Sikander A, Rana SV, Prasad KK. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin Chim Acta 2009; 403: 47-55.
82. Costedio MM, Hyman N, Mawe GM. Serotonin and its role in colonic function and in gastrointestinal disorders. Dis Colon Rectum 2007; 50: 376-388. (Pubitemid 46394454)
83. Chey WD, Pare P, Viegas A et al. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol 2008; 103: 1217-1225. (Pubitemid 351677994)
84. Ford AC, Brandt LJ, Young C et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009; 104: 1831-1843.
85. Talley NJ, Van Zanten SV, Saez LR et al. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001; 15: 525-537. (Pubitemid 32242779)
86. Vakil N, Laine L, Talley NJ et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol 2008; 103: 1906-1919.